ZMC(SH:600216) Zheng Quan Zhi Xing·2025-07-14 10:18Core Viewpoint - Zhejiang Pharmaceutical Co., Ltd. is implementing a differentiated dividend distribution plan for the fiscal year 2024, which has been approved by the board of directors and the annual general meeting of shareholders [5][6]. Group 1: Reasons for Differentiated Dividend - The company held its 10th fourth board meeting on April 14, 2025, where it approved a share repurchase plan through centralized bidding [5]. - A special securities account for share repurchase has been established, and as of the application date for the differentiated dividend, the account holds 9,619,400 shares that will not participate in profit distribution [5][6]. Group 2: Dividend Distribution Plan - The annual general meeting on June 25, 2025, approved a profit distribution plan, which includes a cash dividend of 0.37 yuan per share (tax included) based on the total share capital [5][6]. - The total share capital is 961,637,750 shares, and the shares held in the repurchase account will not be included in the profit distribution [5]. Group 3: Calculation Basis for Dividend - The ex-dividend reference price is calculated using the formula: (previous closing price - cash dividend) ÷ (1 + change in circulating shares ratio) [6]. - Based on the closing price of 15.14 yuan per share on July 1, 2025, the actual ex-dividend reference price is calculated to be 14.77 yuan [6]. Group 4: Conclusion - The legal opinion confirms that the differentiated dividend distribution complies with relevant laws and regulations, and does not harm the interests of the company or all shareholders [6].